- Celgene Corporation (NASDAQ:CELG)
-
Celgene Corporation (NASDAQ:CELG)
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company’s commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST/IMNOVID, THALOMID, ISTODAX and azacitidine for injection. The Company’s preclinical and clinical-stage pipeline includes Oral anti-inflammatory agents, OTEZLA (apremilast); Next generation thalidomide analogues, CC-122 and CC-220; Cellular therapies, PDA-001 and PDA-002; CC-486; Sotatercept and ACE-536; mTOR pathway inhibitors, CC-223 and CC-115; Epigenetic modifiers, EPZ-5676 and CC-292. Its subsidiaries are Celgene Avilomics Research and Celgene Cellular Therapeutics. The Company collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept and ACE-536 to treat anemia in patients with rare blood disorders.
Official website: www.celgene.com
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules